GSK reports 4.05B voting rights at October 31, 2026

Shareholders may use the 4,045,439,182 voting-rights total as the denominator for interest-notification calculations under FCA rules.

Available on EDGAR 11/02/2026 - 10:41 AM EST Accepted by SEC EDGAR 11/02/2026 - 10:41 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

GSK plc reported 4,045,439,182 total voting rights as of October 31, 2026. Its issued share capital comprised 4,316,320,246 Ordinary Shares of 31 ¼ pence each, including 270,881,064 Ordinary Shares held in Treasury. Shareholders may use the voting-rights figure as the denominator for calculating whether they need to notify an interest or a change in interest under the Financial Conduct Authority’s rules.

Key Figures

Total voting rights: 4,045,439,182 voting rights Issued Ordinary Shares: 4,316,320,246 shares Ordinary Shares held in Treasury: 270,881,064 shares +1 more

4 metrics

Total voting rights 4,045,439,182 voting rights As of October 31, 2026; denominator for interest-notification calculations

Issued Ordinary Shares 4,316,320,246 shares As of October 31, 2026

Ordinary Shares held in Treasury 270,881,064 shares As of October 31, 2026

Ordinary Share nominal value 31 ¼ pence per share Issued share capital as of October 31, 2026

Key Terms

total number of voting rights, Ordinary Shares, held in Treasury, denominator, +1 more

5 terms

total number of voting rights regulatory

"the total number of voting rights in the Company is 4,045,439,182"

Ordinary Shares financial

"shares of 31 ¼ pence each (‘Ordinary Shares’)"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

held in Treasury financial

"270,881,064 Ordinary Shares were held in Treasury"

denominator regulatory

"may be used by shareholders as the denominator"

The denominator is the number on the bottom of a fraction that shows the total population or base used to calculate a rate, percentage or ratio — for example, the total shares outstanding when calculating earnings per share, or all trial participants when reporting a safety rate. It matters to investors because changing the denominator (by issuing more shares, changing the population measured, or narrowing the base) can make percentages and per‑unit figures look better or worse even if the underlying raw numbers stay the same, much like changing the size of a pizza makes each slice appear larger or smaller.

Disclosure Guidance and Transparency Rules regulatory

"under the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules"

Disclosure guidance and transparency rules are the standards and regulations that require companies to share clear, timely information about their finances, risks, operations and material events. They matter to investors because consistent, honest reporting is like a car’s dashboard — it reveals the data you need to judge safety and performance and make informed buying or selling decisions. Strong disclosure reduces surprises and helps keep markets fair and efficient.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many voting rights does GSK have?

GSK had 4,045,439,182 total voting rights as of October 31, 2026; shareholders may use that figure as the denominator for calculating whether they need to notify an interest or a change in interest under Financial Conduct Authority rules.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

Issued: 2 November 2026, London UK

Total Voting Rights

In conformity with the Financial Conduct Authority’s Disclosure Guidance and Transparency Rule 5.6.1R, GSK plc (the ‘Company’) hereby notifies the market of the following:

The Company’s issued share capital as at 31 October 2026 consisted of 4,316,320,246 shares of 31 ¼ pence each (‘Ordinary Shares’), of which 270,881,064 Ordinary Shares were held in Treasury.

Therefore, the total number of voting rights in the Company is 4,045,439,182. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules.

Notifications may be sent to company.secretary@gsk.com.

V A Whyte

Company Secretary

2 November 2026

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: November 02, 2026

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc